Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643925 | 0.88 | CASP2 (0.55) | CASP2NAAAFAAHEPHX2 | |
| SCHEMBL4760134 | 0.88 | CASP2 (0.66) | CASP2NAAAALDH1A1HPGDMEN1 | |
| SCHEMBL17753990 | 0.88 | CASP2 (0.66) | CASP2NAAAALDH1A1HPGDMEN1 | |
| SCHEMBL19137795 | 0.86 | CASP2 (0.58) | CASP2NAAAALDH1A1FAAHEPHX2 | |
| SCHEMBL6571910 | 0.86 | CASP2 (0.63) | CASP2NAAAALDH1A1HPGDMEN1 | |
| SCHEMBL6569733 | 0.86 | CASP2 (0.63) | CASP2NAAAALDH1A1HPGDMEN1 | |
| SCHEMBL258662 | 0.85 | CASP2 (0.61) | CASP2NAAAALDH1A1FAAHEPHX2 | |
| SCHEMBL21274180 | 0.85 | CASP2 (0.61) | CASP2NAAAALDH1A1FAAHEPHX2 | |
| SCHEMBL11228741 | 0.85 | CASP2 (0.61) | CASP2NAAAALDH1A1FAAHEPHX2 | |
| SCHEMBL6856630 | 0.85 | CASP2 (0.61) | CASP2NAAAALDH1A1FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | claimed |
| EP-3977112-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | Metabolon Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| CN-113892029-A | Mass spectrometry method for detecting metabolites | 梅塔博隆股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| WO-2020242744-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| CN-101268093-A | Age inhibitors | PHARMAMENS (FR) | 2008-09-17 | — | — | CN | claimed |
| EP-0022022-A1 | Acylated derivatives of taurine and their salts, and process for their preparation | SOCIETE BFB (FR) | 1981-01-07 | — | — | EP | claimed |
| WO-2023168249-A2 | CYSTEAMIDES, THERAPEUTIC COMPOSITIONS THEREOF, AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11352325-B2 | Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3977112-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | Metabolon Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-113892029-A | Mass spectrometry method for detecting metabolites | 梅塔博隆股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-9657046-B2 | Methods for the treatment and prevention of inflammatory diseases | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
| EP-2513132-B1 | METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID | KYTHERA BIOPHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20140301996-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES | UNIVERSITY OF BIRMINGHAM (GB) | 2014-10-09 | — | — | US | disclosed |
| CN-101268093-B | Age inhibitors | PHARMAMENS | 2013-04-03 | — | — | CN | disclosed |
| CN-101268093-A | Age inhibitors | PHARMAMENS (FR) | 2008-09-17 | — | — | CN | disclosed |
| EP-0022022-A1 | Acylated derivatives of taurine and their salts, and process for their preparation | SOCIETE BFB (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352325-B2 | Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals | FUT5, FUT6, ST3GAL3 | CASP2 4374/4885NAAA 748/4885ALDH1A1 1650/4885 |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | FUT5, FUT6, CSGALNACT1 | CASP2 4117/4885NAAA 205/4885ALDH1A1 4000/4885 |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | CASP2 3864/4885NAAA 1801/4885ALDH1A1 1518/4885 |
| US-20140301996-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES | ICOS, HRH2, HRH4 | CASP2 1920/4885NAAA 2526/4885ALDH1A1 886/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | CASP2 4096/4885NAAA 3844/4885ALDH1A1 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.